Table 3.

Cox model for dementia by γ-GT quartiles and NAFLD.

		Incident cases	Person-years	Incident rate*	HR (95% CI)
Overall dementia	γ-GT Q1	64,217	12,804,671	5.01	1 (Referent)
	γ-GT Q2	64,442	12,457,297	5.17	1.02 (1.01–1.03)
	γ-GT Q3	73,458	13,014,700	5.64	1.06 (1.05–1.07)
	γ-GT Q4	70,540	12,130,175	5.81	1.16 (1.15–1.17)
	NAFLD(−)	215,192	38,529,781	5.59	1 (Referent)
	NAFLD(+)	57,465	11,877,062	4.84	1.08 (1.07–1.09)
Early onset dementia	γ-GT Q1	4,117	8,999,668	0.46	1 (Referent)
	γ-GT Q2	4,385	8,417,327	0.52	1.00 (0.96–1.04)
	γ-GT Q3	5,066	8,542,570	0.59	1.01 (0.97–1.06)
	γ-GT Q4	6,347	8,086,032	0.78	1.22 (1.17–1.27)
	NAFLD(−)	14,402	26,077,278	0.55	1 (Referent)
	NAFLD(+)	5,513	7,968,320	0.69	1.02 (0.98–1.06)
Late onset dementia	γ-GT Q1	60,100	3,805,003	15.80	1 (Referent)
	γ-GT Q2	60,057	4,039,970	14.87	1.01 (1.00–1.02)
	γ-GT Q3	68,392	4,472,130	15.29	1.05 (1.03–1.06)
	γ-GT Q4	64,193	4,044,142	15.87	1.13 (1.12–1.14)
	NAFLD(−)	200,790	12,452,504	16.12	1 (Referent)
	NAFLD(+)	51,952	3,908,742	13.29	1.07 (1.05–1.08)
Alzheimer’s disease	γ-GT Q1	47,563	12,804,671	3.71	1 (Referent)
	γ-GT Q2	47,166	12,457,297	3.79	1.02 (1.00–1.03)
	γ-GT Q3	53,476	13,014,700	4.11	1.05 (1.04–1.06)
	γ-GT Q4	50,716	12,130,175	4.18	1.14 (1.13–1.16)
	NAFLD(−)	157,748	38,529,781	4.09	1 (Referent)
	NAFLD(+)	41,173	11,877,062	3.47	1.07 (1.06–1.09)
Vascular dementia	γ-GT Q1	7,350	12,804,671	0.57	1 (Referent)
	γ-GT Q2	7,665	12,457,297	0.62	1.02 (0.99–1.05)
	γ-GT Q3	9,118	13,014,700	0.70	1.10 (1.06–1.13)
	γ-GT Q4	9,310	12,130,175	0.77	1.22 (1.18–1.26)
	NAFLD(−)	25,548	38,529,781	0.66	1 (Referent)
	NAFLD(+)	7,895	11,877,062	0.66	1.11 (1.08–1.15)

Abbreviation: γ-GT, gamma-glutamyl transferase; NAFLD, nonalcoholic fatty liver disease; HR, hazard ratio; 95% CI, 95% confidence interval.

Adjusted for age, sex, body mass index, smoking status, alcohol use, exercise, hypertension, diabetes, dyslipidemia, myocardial infarction, stroke, and socioeconomic status.

*dementia incidence rate was expressed per 1000 person-years.